January 2018
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
Following the publication of the Life Sciences Industrial Strategy, delegates examined the future role of NICE in improving access to new treatments, medical technologies and diagnostic tools, as well as its engagement with the Accelerated Access Review.
Attendees also discussed key issues for funding NICE and the delivery of its Business Plan; lessons learnt from the new approach to the appraisal and funding of cancer drugs - with medicines moving from the Cancer Drugs Fund to routine NHS use - as well as reforms to health technology appraisals and the Highly Specialised Treatments programme.
Further sessions considered the next steps for increasing patient and public involvement, following research carried out to capture patient perspectives; the developing role of NICE guidelines in health and social care and the wider impact of NICE outside of England.
